论文部分内容阅读
我国是肝炎病的高发地区,我国乙肝病毒携带者超过1.2亿人,这一数量占到了世界总数的1/3。每年全国因肝病死亡约30万人。病毒性肝炎每年至少给我国带来直接经济损失500亿人民币。由于我国的肝炎患者居世界首位,其治疗药物市场的潜力之大也让国内外的制药企业跃跃欲试。据统计,目前全国用于治疗肝炎的中、西药物达700多种。目前肝炎市场上治疗乙肝药品的市场居
China is a high-risk area of hepatitis, and China has more than 120 million carriers of hepatitis B virus, accounting for one third of the world total. About 300,000 people die from liver disease each year. Every year, viral hepatitis brings at least 50 billion yuan in direct economic losses to China. As China’s hepatitis patients rank first in the world, the potential of its therapeutic drug market is also tempting domestic and foreign pharmaceutical companies. According to statistics, there are currently more than 700 Chinese and Western medicines used to treat hepatitis in the country. The market for Hepatitis B drugs currently on the hepatitis market